CLINICAL_TRIALS ClinicalTrials.gov record update

Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05485766
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:43.849053+00:00
Published At: 2025-03-20T00:00:00+00:00
Record Updated At: 2025-03-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Triple Negative Breast Neoplasms", "Triple Negative Breast Cancer", "Breast Neoplasms", "Breast Cancer", "BRCA1 Mutation", "BRCA2 Mutation", "BRCA Mutation", "BRCA-Associated Breast Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-03-20"
protocolSection.identificationModule.nctId: "NCT05485766"
protocolSection.identificationModule.officialTitle: "Neoadjuvant and Adjuvant Olaparib Plus Pembrolizumab Following Platinum Based Chemotherapy Plus Pembrolizumab for Germline BRCA Mutated Triple Negative Breast Cancer (WJOG14020B/OPERETTA)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.